No Data
No Data
No Data
No Data
No Data
Atlantic Coastal Acquisition Gets Delisting Determination From Nasdaq
Seeking AlphaFeb 15 10:37 ET
Atlantic Coastal Acquisition Corp. Receives Expected Nasdaq Delisting Determination
NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Atlantic Coastal Acquisition Corp. (NASDAQ:ACAH) (the "Company"), a special purpose acquisition company, announced today that on February 14, 2024, the
AccesswireFeb 14 17:40 ET
Express News | Abpro Announces Filing Of Registration Statement On Form S-4 In Connection With Business Combination Agreement With Atlantic Coastal Acquisition Corp. II; Combined Company Named "Abpro Corporation" Under Ticker "ABP"; $500M Pre-Money Equity Valuation
Moomoo 24/7Jan 22 08:05 ET
Abpro Announces Filing of Registration Statement on Form S-4 in Connection With Business Combination Agreement With Atlantic Coastal Acquisition Corp. II
WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with
GlobeNewswireJan 22 08:00 ET
Atlantic Coastal Acquisition Corp. II Announces Extension of Business Combination Period and Additional Contribution to Trust Account
Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) (the "Company"), a special purpose acquisition corporation, announced that Atlantic Coastal...
PR NewswireOct 18, 2023 16:15 ET
Abpro to Become Publicly Traded via Merger With Atlantic Coastal Acquisition Corp. II
Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases. The transaction values Abpro at $725
BusinesswireSep 21, 2023 16:00 ET
No Data
No Data